ArticlePolymers2022
Synthesis of Cellulose Nanocrystals/HKUST-1 Composites and Their Applications: Crystal Violet Removal and Doxorubicin Loading.
Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 10 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
This study developed a novel composite material containing cellulose nanocrystals (CNCs) and HKUST-1. Here, the addition of CNCs was used to enhance the characteristics of HKUST-1 in terms of surface area, adsorption ability, and functional groups. Here, the fabrication of CNCs@HKUST-1 composites was carried out by adding CNCs into the fabrication process of HKUST-1. The addition of CNCs provides additional functional groups on the surface of composite material which can be used to attach other organic compounds, such as in waste management and drug delivery systems. Here, CNCs@HKUST-1 composites were tested as a material for crystal violet (CV) removal and doxorubicin (DOX) loading. The removal capacity of CNCs@HKUST-1 composite towards CV molecules reached 1182.25 ± 27.74 mg/g, while the loading capacity for DOX drugs was around 1514.94 ± 11.67 mg/g. Both applications showed that CNCs@HKUST-1 composite had higher adsorption capacity and ability compared to its precursor materials, i.e., CNCs and HKUST-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.